论文部分内容阅读
目的 :对托吡酯 (妥泰 )作为加用和单用治疗癫痫的疗效、剂量、加量速度、起效时间及副作用等进行观察研究。方法 :10 7例癫痫患者 ,83例采用加用妥泰治疗 ,2 4例单用妥泰治疗。结果 :共有 10 0例患者完成了 13周疗程的观察。妥泰加用治疗有效率达 80 .2 % ,单用治疗达 79.1% ,妥泰加用治疗在儿童组有效率为 77.5 % ,成人组为 83.3% ,妥泰加用及单用治疗对各型癫痫均有效 ,妥泰起效时间与加量速度显著相关。妥泰起效时间在 4～ 8周达高峰。 10 7例患者 ,副作用发生率为32 .7% ,均较轻。结论 :妥泰加用及单用治疗癫痫均有较好疗效 ,是一种广谱、安全、耐受性好的新型抗癫痫药物
OBJECTIVE: To observe the efficacy, dose, dosage rate, onset time and side effects of topiramate (Totai) as add-on and single-use treatment of epilepsy. Methods: A total of 107 patients with epilepsy were enrolled. 83 patients were treated with topiramate and 24 were treated with topiramate alone. RESULTS: A total of 10 patients completed the 13-week course of treatment. Topotecan with the treatment of effective rate of 80.2%, 79.1% alone treatment, topotecan plus treatment in children effective rate of 77.5%, 83.3% of adults, topotecan plus and monotherapy Type epilepsy are effective, topiramate onset time and the rate of increase was significantly correlated. Topotec onset time reached the peak in 4 to 8 weeks. 10 7 patients, the incidence of side effects was 32.7%, were lighter. Conclusion: Both topiramate and monotherapy have better therapeutic effect on epilepsy, which is a new anti-epileptic drug with broad spectrum, safety and tolerability